Cocaine Dependence Clinical Trial
Official title:
Exploring Gender Differences in the Neural Substrates of Stress Induced Drug Craving
Cocaine dependence is an insidious disease underscored by a powerful proclivity to relapse
despite an individual's ability to recognize the deleterious consequences of continued drug
use. To date, there are only a limited number of treatments, and no FDA approved medications
for the treatment of cocaine dependence. Attempts to find reliable and successful treatments
for cocaine dependence may be marred by gender differences in brain chemistry, structure, and
function that are manifested as drug craving and relapse. For example, cues, drug exposure,
and stress promote relapse, yet females appear be more susceptible to stress induced relapse,
while males may be more susceptible to cue induced relapse. Therefore identifying the neural
substrates involved in processing the valence of internal and external stimuli may provide
further insight into cocaine dependence and provide more effective therapeutic strategies
aimed at preventing relapse.
Corticotropin releasing hormone (CRH) is a pharmacological activator of the hypothalamic
pituitary adrenal (HPA) axis, and has been implicated in stress induced drug relapse.
Corticotropin releasing hormone receptors are located at extrahypothalamic brain nuclei that
have been implicated in determining the significance of both internal (somatic) and external
(environmental) stimuli. The primary directive of this pilot project is to utilize functional
magnetic resonance imaging (fMRI) to identify possible brain nuclei associated with with
stress induced drug craving in cocaine dependent females.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04994821 -
tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
|
Phase 2 | |
| Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
| Completed |
NCT01402492 -
Cocaine Use Reduction With Buprenorphine
|
Phase 2/Phase 3 | |
| Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
| Completed |
NCT00880997 -
The Efficacy of Doxazosin for Cocaine Users
|
Phase 1 | |
| Completed |
NCT00585520 -
Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues
|
Phase 1 | |
| Completed |
NCT00566969 -
Cocaine Withdrawal and Pharmacotherapy Response
|
N/A | |
| Completed |
NCT00368290 -
Modafinil Treatment for Cocaine Dependence and HIV High-Risk Behavior
|
Phase 2 | |
| Completed |
NCT00385801 -
Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence
|
Phase 2 | |
| Completed |
NCT00322309 -
Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects
|
Phase 2 | |
| Completed |
NCT00842517 -
Long Term Maintenance of Drug Abstinence
|
Phase 1 | |
| Completed |
NCT00167245 -
Topiramate for Alcohol and Cocaine Dependence
|
Phase 2 | |
| Not yet recruiting |
NCT05974202 -
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
|
Phase 2 | |
| Completed |
NCT04411914 -
Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid
|
Phase 1 | |
| Active, not recruiting |
NCT03266939 -
Rebalancing the Serotonergic System in Cocaine Dependence
|
Phase 1 | |
| Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
| Recruiting |
NCT06159387 -
Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts
|
Phase 4 | |
| Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
| Completed |
NCT02018263 -
Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans
|
Phase 1 | |
| Completed |
NCT01573273 -
Oxytocin in Cocaine Dependence
|
N/A |